{"id":"NCT00647699","sponsor":"Glaukos Corporation","briefTitle":"Corneal Collagen Cross-linking for Progressive Keratoconus","officialTitle":"Safety and Effectiveness of the UV-X System for Corneal Collagen Cross-Linking in Eyes With Progressive Keratoconus","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-12","primaryCompletion":"2011-04","completion":"2011-04","firstPosted":"2008-04-01","resultsPosted":"2016-07-07","lastUpdate":"2021-04-26"},"enrollment":147,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Progressive Keratoconus"],"interventions":[{"type":"DRUG","name":"riboflavin ophthalmic solution","otherNames":[]},{"type":"DEVICE","name":"UVA Irradiation","otherNames":["UV-X Illumination System"]}],"arms":[{"label":"Corneal Collagen Cross-linking (CXL) Treatment Group","type":"ACTIVE_COMPARATOR"},{"label":"Control Group","type":"SHAM_COMPARATOR"}],"summary":"Prospective, randomized multicenter study to determine the safety and effectiveness of performing cornea collagen cross-linking (CXL) using riboflavin and UVA light in eyes with progressive keratoconus.","primaryOutcome":{"measure":"Mean Change From Baseline in Maximum Keratometry (Kmax)","timeFrame":"baseline,12 months","effectByArm":[{"arm":"Corneal Collagen Cross-linking (CXL) Treatment Group","deltaMin":-1.7,"sd":4.7},{"arm":"Control Group","deltaMin":0.6,"sd":2.8}],"pValues":[]},"eligibility":{"minAge":"14 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":2},"locations":{"siteCount":10,"countries":["United States"]},"refs":{"pmids":["22692521"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":73},"commonTop":["Corneal opacity","Punctate keratitis","Eye pain","Corneal striae","Corneal epithelial defect"]}}